METiS TechBio (剂泰科技)
Category: AI in Biotech / Drug Discovery
AI-driven nanomaterial and drug delivery platform company that went public on HKEX as the world's first AI drug delivery stock METiS TechBio (剂泰科技) was founded in 2020. The company is led by Dr. Chris Lai (赖才达). Based in Beijing, China. Team size: 201-500. Total funding raised: $315M. Latest round: IPO. Key investors include CICC Capital; HongShan (红杉中国); PICC Capital; China Life Private Equity; 5Y Capital (五源资本); Frees Fund (峰瑞资本); Lightspeed China (光速光合); Sourcode Capital (源码资本); CMB International; Monolith; Yayi Capital; Beijing Medical and Health Industry Investment Fund; Daxing Industrial Investment Fund; BlackRock (cornerstone); UBS AM Singapore; Mirae Asset; ORIX; Deerfield; RTW; Lake Bleu Capital (清池资本); Walden International (华登国际); Hillhouse (高瓴); IDG Capital.
- Founded
- 2020
- Headquarters
- Beijing, China
- Team size
- 201-500
- Total funding
- $315M
Value proposition
Using AI to design and optimize nanoscale drug delivery systems (LNPs, formulations) to dramatically accelerate drug development timelines and enable targeted delivery to specific organs and tissues
Products and solutions
NanoForge (global first AI nanodelivery platform), AiLNP, AiRNA, AiTEM, AiProtein (AI protein/antibody design platform + AARON agent, launched May 2026), MTS-004 (PBA, first AI-enabled formulation drug to complete Phase III in China), MTS-105 (in vivo mRNA-encoded TCE solid tumor therapy), MTS-128 (trispecific TCE, licensed globally to Boulevard Bio Jun 2026), OpenCGT platform for cell and gene therapy (collaborations >RMB 6B)
Unique value
World's first and only end-to-end AI nanodelivery platform (NanoForge) with the largest ionizable lipid library globally, proprietary lipid generation algorithms, and lipid language models — enabling targeted delivery to 8 key organs/tissues
Target customer
Global pharmaceutical companies, biotech firms, and medical research institutions seeking AI-powered drug formulation and delivery solutions
Industries served
Pharmaceuticals (small molecule, nucleic acid, biologics); Cell & Gene Therapy; Animal Health; Anti-aging therapeutics
Technology advantage
Proprietary AI foundation models + quantum chemistry/molecular dynamics simulations + high-throughput screening; world's largest ionizable lipid library (millions); only lipid de novo generation algorithm and lipid language model globally; first end-to-end LNP screening platform; AI+multi-scale simulation small molecule formulation platform; 224 patent applications filed, 52 granted
How they differentiate
Unlike competitors focused on AI drug discovery (molecule finding), METiS specializes in AI-driven drug DELIVERY (nanomaterials, LNPs, formulations) — the "last mile" problem in drug development. Only company with end-to-end AI nanodelivery platform covering lipid design, LNP formulation, mRNA optimization, and small molecule formulation. Incubated by XtalPi but operates in a complementary niche.
Main competitors
XtalPi (晶泰科技) - HKEX-listed AI drug discovery company, also METiS' incubator; Insilico Medicine - HKEX-listed AI drug discovery company; Standigm, Spark Biopharma
Key partnerships
Boulevard Bio/Deerfield (MTS-128 global exclusive license, Jun 2026, $20M upfront / up to $1.6B milestones), Jiangsu Hengrui Pharmaceuticals (AiTEM local deployment, Aug 2026), Luye Pharma (AI drug delivery strategic partnership, Sep 2026), Grit Biotechnology (immune-targeted LNP/OpenCGT, May 2026), WestVac Biopharma (personalized mRNA cancer vaccines, AccurEdit Therapeutics, Evopoint Biosciences, Voronoi
Notable customers
30+ global pharma/biotech partners, Boulevard Bio (MTS-128 license), Jiangsu Hengrui Pharmaceuticals (AiTEM platform deployment), Luye Pharma (first AI drug delivery strategic partner), Grit Biotechnology, WestVac Biopharma, AccurEdit Therapeutics, Evopoint Biosciences, Voronoi
Major milestones
2020: Founded, incubated by XtalPi, 2021–2025: Series A–D, MTS-004 Phase III complete, NanoForge launch, MIT TR50, 2026-05-13: HKEX listing 7666.HK (~HK$2.1B), 2026-05-18: Grit Biotech OpenCGT collab (aggregate >RMB 6B), 2026-05-26: AiProtein + AARON launch, 2026-06-05: Full greenshoe exercised, 2026-06-30: Boulevard Bio MTS-128 deal ($20M upfront / up to $1.6B), 2026-08: Hengrui AiTEM deployment, H1 2026 revenue RMB 154.3M
Growth metrics
2025 revenue: RMB 105M (~$14.5M) primarily from MTS-004 collaboration upfront (NOT ¥1.05B); H1 2026 revenue RMB 154.3M (+13,399% YoY, +47% vs full-year 2025), adjusted net loss RMB 51.1M (narrowed 56.4%); IPO raised HK$2.1B base / ~HK$2.43B with full greenshoe (Jun 2026); market cap ~HK$12.1B at IPO; HK public offering ~6,911x oversubscribed; Stock Connect inclusion Sep 2026
Market positioning
First-mover and global leader in AI-driven nanodelivery; CB Insights ESP matrix "LEADER" for AI-driven drug formulation; world's first AI drug delivery stock on HKEX; positioned as the "Space X of pharma" for nano-rocket drug delivery
Geographic focus
China (primary R&D and commercialization base), US (METiS Therapeutics in Cambridge, MA), global pharma partnerships
Patents and IP
224 patent applications filed, 52 granted as of IPO date (May 2026)
About Dr. Chris Lai (赖才达)
Ex-McKinsey & Company Strategic Consultant; MIT PhD in Chemical Engineering (Novartis-MIT Center for Continuous Manufacturing); Founder of AquaFresco (water-tech startup); MIT Innovation Award in Clean Energy and Water Treatment
Latest news about METiS TechBio (剂泰科技)
More AI in Biotech / Drug Discovery companies
Official website: https://www.metistechbio.com